Versum Materials — Proxy Contest (April 2019)
37 slides from Versum Materials's proxy contest presentation, Apr 2, 2019
Slide 1: Merck KGaA, Darmstadt, Germany Investor Presentation
April 2, 2019 MERCK KGAA, DARMSTADT, GERMANY INVESTOR PRESENTATION
Slide 2: Disclaimer
Disclaimer Publication of Merck KGaA, Darmstadt, Germany . In the United States and Canada the group of companies affiliated with Merck KGaA, Darmstadt, Germany, operates under individual business names (EMD Serono, Millipore Sigma, EMD Performance Materials) . To reflect such fact and to avoid any
Slide 3: Disclaimer: Forward-Looking Statements and Additional Important Information
3 Disclaimer Cautionary Statement Regarding Forward - Looking Statements This communication may contain forward - looking statements based on current assumptions and forecasts made by Merck KGaA, Darmstadt, Germany management . Various known and unknown risks, uncertainties and other factors could l
Slide 4: Key topics to be addressed
Key topics to be addressed 4 Summary of Merck KGaA, Darmstadt, Germany’s superior proposal to acquire Versum Merck proposal provides superior value to Versum shareholders Market reaction supports our proposal Strong industrial logic in combination with Merck, KGaA, Darmstadt, Germany Flawed process
Slide 5: Summary of Merck KGaA, Darmstadt, Germany's superior proposal to acquire Versum
SUMMARY OF MERCK KGAA, DARMSTADT, GERMANY’S SUPERIOR PROPOSAL TO ACQUIRE VERSUM
Slide 6: Our superior proposal for Versum shareholders
Our superior proposal for Versum shareholders 6 Our superior proposal • Superior to Entegris’ proposal and • in the best interest of Versum stakeholders All - cash proposal Substantial premium Attractive valuation Certainty and Conviction Beneficial for other stakeholders • ~52% premium over unaffec
Slide 7: Significant discount to current trading
7 Significant discount to current trading Entegris’ deal is currently valued at a significant discount to Versum’s prevailing stock price and to our $48 bid Value proposition is inferior Analysis by Versum’s financial advisor, Lazard, clearly shows that our offer commands higher valuation than the E
Slide 8: Merck proposal provides superior value to Versum shareholders
MERCK PROPOSAL PROVIDES SUPERIOR VALUE TO VERSUM SHAREHOLDERS
Slide 9: Our $48 offer is a substantial premium for Versum shareholders
9 Our $48 offer is a substantial premium for Versum shareholders Source: Bloomberg market data as of 1 - Apr - 2019 1 Premium to Versum share price as of 25 - Jan - 2019 ($31.65). 2 Premium to offer price implied by Entegris share price as of 1 - Apr - 2019 ($36.78) at 1.12 exchange ratio. 3 Premium
Slide 10: Our Proposal represents a best-in-class valuation multiple
13.4 x 13.3 x 13.1 x 13.0 x 12.3 x 11.9 x 10.7 x 10.1 x 10.0 x Entegris / ATMI Our Offer for Versum Platform Specialty / Alent Platform Specialty / OM Group Elec. Chem. Cabot Microelectronics / KMG Carlyle / Atotech Merck / AZ Electronic Materials Entegris Offer for Versum Platform Specialty / MacDe
Slide 11: Lazard's published analysis supports our proposal being superior
The published financial analysis of Lazard – Versum’s own financial advisor – supports our view that our Proposal is superior to the Entegris acquisition Notwithstanding the projections , Our Proposal is superior to Lazard’s valuation of Versum on a standalone basis 1 … 11 … and when compared to Laz
Slide 12: Projections considered by Versum materially more aggressive than consensus
12 Projections considered by Versum materially more aggressive than Wall Street consensus Versum 12 Entegris Source: Broker research, SEC filings, Bloomberg market data as of 1 - Apr - 2019 Note: CAGRs refer to 2018A – 2021E compounded growth rates. Sales Adj. EBIT Adj. EBITDA 3.9 % CAGR 9.7% CAGR 3
Slide 13: Our Proposal provides certainty for Versum shareholders
13 Our Proposal provides certainty for Versum shareholders, and our unwavering commitment to the deal is exemplified by our actions We are committed to this deal Regulatory • No anticipated regulatory issues • Regulatory process is underway and we expect that regulatory clearances will be received i
Slide 14: Market reaction supports our proposal
MARKET REACTION SUPPORTS OUR PROPOSAL
Slide 15: Market has not moved significantly since announcement of our Proposal
Source: CapIQ. 1 Pure - Play Peers: Rogers, Cabot Microelectronics, and Element Solutions 15 Market has not moved significantly since the announcement of our Proposal 1 Stock price performance since our Proposal 21.7% (2.5%) (1.9%) 2.6% 4.5% (10.0%) 0.0% 10.0% 20.0% 30.0% 26-Feb-19 4-Mar-19 8-Mar-19
Slide 16: Market reaction supports view that our proposal is superior
$50.40 $41.19 $48.00 0 2000 4000 6000 8000 10000 12000 14000 16000 18000 $20 $25 $30 $35 $40 $45 $50 $55 1-Jan-2019 11-Jan-2019 21-Jan-2019 31-Jan-2019 10-Feb-2019 20-Feb-2019 2-Mar-2019 12-Mar-2019 22-Mar-2019 1-Apr-2019 Volume Versum Stock Price Entegris Deal Value¹ Merck KGaA, Darmstadt, Germany
Slide 17: Entegris acquisition could result in significant downside for Versum shareholders
$ 48.00 $ 50.40 $ 41.19 $ 37.14 $ 39.24 Our Offer for Versum Current Versum Price (1-Apr-2019) Current Implied Entegris Offer Implied Entegris Offer on Initial Combination Annoucement Implied Entegris Offer on Date "Newly Found" Synergies were Announced 17 Entegris acquisition could result in signif
Slide 18: Material downside risk to Versum shareholders in Entegris stock
$41.19 $50.40 $ 15 $ 20 $ 25 $ 30 $ 35 $ 40 $ 45 $ 50 $ 55 Sep-16 Nov-16 Jan-17 Apr-17 Jun-17 Aug-17 Oct-17 Dec-17 Mar-18 May-18 Jul-18 Sep-18 Nov-18 Jan-19 Apr-19 $ 48.00 $ 38.80 $ 49.93 $ 15 $ 20 $ 25 $ 30 $ 35 $ 40 $ 45 $ 50 $ 55 Sep-16 Dec-16 Mar-17 Jun-17 Sep-17 Dec-17 Mar-18 Jun-18 Sep-18 De
Slide 19: Strong industrial logic in combination with Merck KGaA, Darmstadt, Germany
STRONG INDUSTRIAL LOGIC IN COMBINATION WITH MERCK, KGAA, DARMSTADT, GERMANY
Slide 20: Who we are
20 Sales by segment Sales by region Total capex and R&D * ($bn) Sales development * ($bn) Healthcare: 42% Life Science: 42% Performance Materials: 16% Europe: 31% Asia - Pacific: 33% Middle East & Africa: 4% Latin America: 6% North America: 26% We are a leading science and technology company , activ
Slide 21: Track record of successful acquisitions and financial flexibility
We have an outstanding track record of successful acquisitions and the financial flexibilities for further growth ▪ Strong track record of successful acquisitions, particularly in the U.S. ▪ Over the last 10 years, we have completed acquisitions in the U.S. with a total transaction value of ~$24bn 1
Slide 22: Why Versum and Merck KGaA fit so well together
22 Text slides and Textboxes Why Versum and Merck KGaA, Darmstadt, Germany, fit so well together – creating a leading electronic materials player 1 2 3 4 Create a leading player • Create one of the leading electronic materials players focused on the semiconductor and display industries with cutting
Slide 23: Flawed process run by Versum, with a one-track focus on Entegris acquisition
FLAWED PROCESS RUN BY VERSUM, WITH A ONE - TRACK FOCUS ON ENTEGRIS ACQUISITION
Slide 24: Versum's process rushed, flawed, not a rigorous assessment
Versum’s entire process to date has been rushed, flawed, and is not the result of a rigorous assessment Versum’s Flawed Process Rushed discussions between the parties Minimal due diligence and limited negotiation No other alternatives considered No apparent review of buyer landscape R ejec
Slide 25: Cost synergies increased to a level inconsistent with Versum's cost base
25 Cost synergies have been increased to a level which seems inconsistent with Versum’s cost base Entegris / Versum announced synergies are overly aggressive and unreasonably optimistic Announced cost synergies as a % of SG&A for precedent transactions 1 Announced total synergies as a % of sales for
Slide 26: Versum's new synergies are speculative and illusory
26 Versum’s new synergies are speculative and illusory Source: Public filings What this means Versum and Entegris are trying to salvage their deal by attempting to improve their value proposition – while ignoring associated execution risks and costs to achieve Further evidence of a poor process If
Slide 27: Market seems skeptical of revised synergies
$36.78 $ 25 $ 30 $ 35 $ 40 1-Jan 11-Jan 21-Jan 31-Jan 10-Feb 20-Feb 2-Mar 12-Mar 22-Mar 1-Apr Entegris Market seems skeptical of revised synergies 25 - Jan - 19 undisturbed date 27 At the announcement of the acquisition on 28 - Jan - 2019, Entegris / Versum predicted $75mm in synergies Initial Enteg
Slide 28: Versum appears to have operated with a one-track process
“Following Versum’s spin - off from Air Products in 2016, the Versum board of directors, together with Versum’s senior management team, has from time to time considered... the possibility of a combination with Entegris... ... Versum’s senior management and the Versum board of directors were therefor
Slide 29: Retention bonuses for Versum senior executives out of touch
29 Recently announced retention bonuses for Versum senior executives are out of touch and give wrong incentive to management x Annual Base Salary 2 • On 15 - Mar - 2019, Versum and Entegris ' board of directors approved a cash based “retention bonus” program for Versum senior executives • Comprised
Slide 30: Versum's poor governance around Entegris transaction
VERSUM’S POOR GOVERNANCE AROUND ENTEGRIS TRANSACTION
Slide 31: Pro forma governance favors Entegris
31 Pro Forma governance favors Entegris, and continues a number of structural characteristics of Entegris that are not best in class Versum 1 Versum 2 Versum 3 Versum 4 (Existing Chair) Entegris 1 Entegris 2 Entegris 3 Entegris 4 Entegris 5 (Existing CEO) 5 4 Proposed post - closing Board of Directo
Slide 32: Aggressive adoption of poison pill detrimental to shareholder value
Aggressive adoption of poison pill is to the detriment of shareholder value Poison pill adoption as immediate reaction to our offer Poison pill out of step with governance best practices • Versum did not engage with us upon receipt of our proposal • Instead, Versum adopted a poison pill only one day
Slide 33: Limited opportunity for Versum employees and community under Entegris ownership
33 Limited opportunity for Versum employees and community under Entegris ownership ▪ After the Entegris acquisition, the combined business will be operated from Entegris’ headquarters in Billerica, Massachusetts, >2,500 miles away from Tempe, Arizona x Entegris proposal: Combined company headquarter
Slide 34: Conclusion
CONCLUSION
Slide 35: Why Merck KGaA is the right owner of Versum
35 Our proposal is superior We are the right owners of this asset The transaction process has been flawed We are committed to this deal Why Merck KGaA, Darmstadt, Germany, is the right owner of Versum • Leading science and technology company, active in 3 areas: Healthcare, Life Science and Performan
Slide 36: A compelling proposal for all stakeholders
36 A compelling proposal for all stakeholders Providing leading - edge technology backed by the capabilities, scale and quality of Merck KGaA, Darmstadt, Germany Truly global footprint and close proximity to customers worldwide Combines innovation strength to better serve our customers in a rapidly
Slide 37: Slide 37